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Retinal ganglion cells (RGCs) are the bridging neurons that connect the retinal input to
the visual processing centres within the central nervous system. There is a remarkable
diversity of RGCs and the various subtypes have unique morphological features, distinct
functions, and characteristic pathways linking the inner retina to the relevant brain
areas. A number of psychophysical and electrophysiological tests have been refined to
investigate this large and varied population of RGCs. Technological advances, such as
high-resolution optical coherence tomography imaging, have provided additional tools to
define the pattern of RGC involvement and the chronological sequence of events in both
inherited and acquired optic neuropathies. The mechanistic insights gained from these
studies, in particular the selective vulnerability and relative resilience of particular RGC
subtypes, are of fundamental importance as they are directly relevant to the development
of targeted therapies for these invariably progressive blinding diseases. This review
provides a comprehensive description of the various types of RGCs, the developments in
proposed methods of classification, and the current gaps in our knowledge of how these
RGCs are differentially affected depending on the underlying aetiology. The synthesis
of the current body of knowledge on the diversity of RGCs and the pathways that
are potentially amenable to therapeutic modulation will hopefully lead to much needed
effective treatments for patients with optic neuropathies.
Keywords: retinal ganglion cell, optic neuropathies, hereditary optic neuropathies, acquired optic neuropathies,
electrophysiological tests, neuro-ophthalmology
INTRODUCTION
It was a clinical ophthalmologist, and an unusually interesting one, who first proposed that different
fibres in the optic nerve carry different attributes of the retinal image, such as colour and spatial
detail. Born in Charleston in 1830, John Julian Chisolm graduated from the Medical College
of South Carolina in 1850 and gained further training on two visits to Europe (1). After the
bombardment of Fort Sumter, he was commissioned into the Confederate Army and within 4
months had published the first of three editions of his “Manual of Military Surgery.” In the years
after the Civil War, he specialised in ophthalmology and in 1869, he reported, in the Moorfields
house journal, how form vision had recovered before colour vision in a case of neuritis, leading him
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to ask “. . .whether there are special nerve fibres, for the
recognition of special colours, independent of those used in the
clear definition of objects.” (2). As early as the eighteenth century,
there had been suggestions that there are different retinal fibres
for different colours [e.g., (3, 4)], but Chisolm’s is likely to be one
of the first suggestions that different attributes of the image—such
as form and colour—are carried by different fibres.
Today, it is clear that the retina does not deliver to the brain a
pixel-by-pixel representation of the pattern of light falling on the
photoreceptors. There are about 120 million rods and 6 million
cones, whilst the output of the retina is transmitted by around 1.2
million retinal ganglion cells. Thus, there exists significant “pre-
processing” of the visual signal by the retinal neuronal layers.
The retinal ganglion cells (RGCs) extract in parallel different
attributes of the image—spatial contrast, colour, motion, flicker,
fine and coarse textures, absolute light level—and deliver this
information to different sites within the visual system (5, 6).
At least 18 different types of ganglion cells are now thought
to be present in the primate and human retina, all of them
functionally and morphologically distinct (7, 8). The individual
types gain their functional specificities in turn from dedicated
circuits that lie between the photoreceptors and the ganglion cells
(9). The primate retina is currently thought to include 2 types of
horizontal cells, 12 types of bipolar cells and more than 25 types
of amacrine cells (Table 1).
Our purpose in this review is to provide clinicians with a brief
survey of the different types of ganglion cells to highlight the
possibility of either selective impairment or selective survival of
particular types of cells. Subsequently, we discuss both clinical
and research methods for evaluating the structure and function
of RGCs, and survey a number of relevant clinical conditions
before briefly discussing future avenues of research. This review
will focus on primate and human studies. Lower mammals
appear to enjoy a richer range of ganglion cell types with 40
or more different types having been reported in the mouse (16,
17). It is certainly attractive to consider the extensive literature
devoted to the mouse since a remarkable array of histological,
physiological and genetic methods have become available to
study murine ganglion cells over the past two decades—methods
that cannot all be applied to primates. In many areas, there is
wide conservation across mammalian phylogeny, not only of cell
morphologies, but also of the physiological circuits that underlie
the functional specialisation of particular types of cell. On the
other hand, the retina of each species is well adapted to the
visual theatre into which that species is born, having evolved to
match the requirements of that animal’s visual world and to serve
the animal’s survival and reproduction (18). Analogies between
different species may, therefore, sometimes be misleading (19).
Even between macaques and humans, there may be occasional
differences in the genes expressed in otherwise corresponding
types of ganglion cells (20).
“Midget” and “parasol” types comprise more than 80% of all
ganglion cells in human and primate retinas (20). Given this
predominance, it is tempting to neglect the many minority types,
but functional importance should not be equated with relative
numbers. Midget and parasol cells have relatively small dendritic
fields and therefore, large numbers are needed to tessellate—to
tile—the retina. Typically, the rarer ganglion cells have larger,
often much larger, dendritic fields (7), and thus many fewer are
needed to tesselate the entire retina. Yet, these wide-field cells
may have a critical functional role, perhaps in everyday life or
perhaps in unusual, but life-threatening conditions. In the case
of several wide-field ganglion cells, this function is still unknown,
and it may fall to an alert clinician, in the tradition of Chisolm, to
detect the selective impairment that provides important clues.
Classification of Ganglion Cells—Methods
The taxonomy and the nomenclature of ganglion cells, like
taxonomies and nomenclatures in other branches of biology,
have generated unexpectedly contentious debates, especially
when different methods of classification give different solutions
or when nomenclatures are translated from one species to
another (21). We briefly survey the several techniques that have
led to the current taxonomy of ganglion cells. The alternative
methods can themselves be grouped into anatomical, molecular,
and functional classification.
Anatomical Classification
The cell bodies of most ganglion cells, and the layer formed by
their axons, lie close to the inner limiting membrane adjacent to
the vitreous, although occasional “displaced” ganglion cells are
seen among amacrine cells in the inner nuclear layer [(22, 23),
p. 309]. In the central regions of the retina, there are up to eight
layers of ganglion cells, whereas in the far periphery, near the ora
serrata, there are only sparse clumps of two or three ganglion cells
with gaps between them (23).
Morphology
A fundamental basis for classification—and the one mainly
adopted in the present review—is the size and morphology of the
cell body and dendrites, as well as the extent of the dendritic field
(Figure 1). Already in 1893, using the silver staining method of
Golgi, Cajal distinguished several types of ganglion cells by such
features, but it was not until 1935 that the predominant ganglion
cells of the central region of the primate retina, the midget cells,
were described by Stephen Polyak (who had not yet anglicised his
name) (24).
Upstream Connexions: The Input Circuits and the
Stratification of Dendrites
The functional properties of a given ganglion cell must
necessarily depend on the excitatory and inhibitory inputs
it receives from bipolar cells and from amacrine cells. The
many different types of amacrine cells allow the construction
of specialised circuits that determine the responses of their
associated ganglion cells. In principle, it would be possible for two
ganglion cells of identical morphology to receive different inputs
and thus differ in their functional properties.
A fundamental basis for classifying ganglion cells is therefore
the stratum, or strata, of the inner plexiform layer (IPL) in
which their dendrites extend. Some are “monostratified,” their
dendrites confined to one stratum; some are “bistratified,” having
two distinct layers of dendrites (Figure 1). The level or levels
at which the dendrites of a given ganglion cell stratify are very
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characteristic (6). One gross division is between the inner and
outer layers of the inner plexiform layers. Bipolar cells of the OFF
type predominantly make contact with ganglion cells in the outer
part whereas bipolar cells of the ON-type predominantly synapse
in the inner part.
Downstream Connexions: The Projections of Retinal
Ganglion Cells
A further anatomical classification, and one of special interest
to the neuro-ophthalmologist, can be based on the projection
sites of each class of ganglion cell. Besides the lateral geniculate
nucleus, there are several other brain areas that receive direct
projections from the retina, including the superior colliculus, the
pulvinar complex, the olivary pretectal nucleus, the supraoptic
nucleus of the optic tract, the paraventricular nucleus, the
suprachiasmatic nucleus, and the dorsal raphe nucleus (see
Figure 2) (25–27).
Classically, the projections of the ganglion cell layer could be
established by anterograde tracing, e.g., by intraocular injection
of a radioactive agent or cholera toxin subunit B (28), but
TABLE 1 | The number of types of photoreceptors, bipolar cells, and retinal
ganglion cells in different species.
Mouse Cat Rabbit Primates













Bipolar cells ∼15 (11) ∼9 (12) ∼13 (13) ∼12 (14)
Retinal ganglion
cells
∼30 (5) ∼23 (12) ∼20? (15) Up to 18
anterograde tracing of this kind does not identify the type,
or types, of ganglion cell in which the projection originates.
Retrograde methods, e.g., injecting horseradish peroxidase into
the central site, allow specific ganglion cells to be labelled in the
retina. An example would be the study by Cowey et al. showing
retrograde labelling of several types of primate ganglion cells—
including parasol and midget—after injections to the pulvinar
(29). One modification of the retrograde method was introduced
by Rodieck and Watanabe, who used a fluorescent marker for
retrograde tracing and then, in an in vitro preparation, injected
rhodamine-conjugated horseradish peroxidase into individual
cells that had been labelled by the retrograde marker—a
procedure that gave better filling of dendrites than did simple
retrograde tracing with horseradish peroxidase (30).
Molecular Classification
The Golgi method is “noted for its fickleness” (31): this is its
strength, in that it exquisitely reveals isolated neurons against a
pale background, but it is also its weakness, in that the random
staining is unpredictable and not specific to a particular type of
cell (32). What are obviously desirable, especially for quantitative
purposes, are methods that label either a single class of ganglion
cells or only a small number of classes. In the case of lower
mammals, many molecular markers (e.g., using antibodies or
gene expression) have been developed to identify individual
classes (Table 2) [e.g., (46)].
There has been less work of this kind in primates, but of
particularly note is the work by Peng et al. (19) and Yan et al.
(20) who identified RNA expressed in individual cells from
macaque and human retinas (Table 3). In macaque, they were
able to group peripheral ganglion cells into 18 clusters and foveal
ganglion cells into 16 clusters. Three of the peripheral clusters
in macaque retina (and two in the case of human) expressed
OPN4, the gene for melanopsin and thus a marker of intrinsically
FIGURE 1 | Schematic description of retinal ganglion cells. Morphological types of RGCs are classified based on soma size and dendrite morphology (by
Ungsoo S. Kim).
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FIGURE 2 | Pathways of retinal ganglion cells. OPN, olivary pretectal nucleus; RGCs, retinal ganglion cells; SC, superior colliculus; SCN, suprachiasmatic nucleus (by
Ungsoo S. Kim).
TABLE 2 | Antibodies used in immunohistochemistry for retinal ganglion cells.
Antigen Host species Specificity References
βIII-tubulin Mouse Monoclonal (33)
Islet-1 Mouse Monoclonal (34)
Syntaxin-1 Mouse Monoclonal (35)
GFAP Mouse Monoclonal (36)
ED1 Rabbit Monoclonal (37)
Brn3a Goat Polyclonal (38)
Thy1 (CD90) Mouse Monoclonal/Polyclonal (39)
CaBP (DB3a) Mouse Monoclonal (40)




photosensitive RGCs (ipRGCs). Fourteen of the foveal clusters
corresponded to peripheral clusters. Although a similar set of
transcription factors is used in mouse and primate ganglion cells,
there was little correspondence in the detailed RNA expression
TABLE 3 | Expression molecular markers of major retinal ganglion cells in
primates.
Type of retinal ganglion cells Expression molecular
markers
References
ON-midget RGCs TPBG, GUCY1A3 (47)
OFF-midget RGCs TBR1, GUCY1A3 (19)
ON-parasol RGCs CHRNA2, SPP1, RBPMS2 (19, 48)
OFF-parasol RGCs CA8, SPP1, RBPMS2 (19, 48)
Large sparse RGCs SATB2 (49)
ipRGCs* OPN4 (50, 51)
*ipRGCs, intrinsically photosensitive retinal ganglion cells.
patterns of individual cell types. In particular, there was no clear
mouse equivalent of the midget ganglion cell of the primate.
The patterns of RNA expression were very similar for human
and macaque retinas, but occasional differences were seen. For
example, the gene RBPMS2 was expressed in human, but not
macaque midget ganglion cells. In the present context, it is
significant that genes known to be associated with glaucoma
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were found to be predominantly expressed in ganglion cells,
sometimes selectively—e.g., SIX6 in midgets (19).
Functional Classification
In functional experiments, a physiological measure of a cell’s
response is recorded when the retina is stimulated with a
specific stimulus. Psychophysical work has often guided the
choice of stimulus. In the second half of the twentieth
century, psychophysicists endeavoured to isolate “mechanisms”
or “channels” within the visual system. These constructs were
hypothetical, but the hope—not without foundation—was that
they corresponded to independent neural channels. The isolation
of a given channel was achieved by construction of a stimulus
to which the channel might be maximally sensitive and by the
use of selective adaptation stimuli to reduce the sensitivity of
other channels [e.g., (52–54)]. The techniques that were honed by
psychophysicists were often adopted by electrophysiologists and
applied to individual ganglion cells. The same techniques often
also inspired new clinical testing methods, such as frequency-
doubling perimetry, designed to isolate channels with non-
linear responses (55). Psychophysics has also inspired the
instruments used to deliver the carefully crafted stimuli needed in
electrophysiological work—Maxwellian-view optics in the 1960’s,
computer-controlled CRT displays in the 1980’s, and digital light
processors in this century.
The celebrated study of Kuffler initiated the extracellular
recording of action potentials from individual ganglion cells in
the mammalian retina by means of fine-tipped microelectrodes
(56). Kuffler demonstrated the antagonistic centre-surround
arrangement that characterises the receptive fields of many
ganglion cells: stimulation of the centre of the receptive field
evokes an ON response in some cells and an OFF response in
others, whereas stimulation of a surrounding region evokes the
opposite response (Figure 3).
A pioneer in the study of primate RGCs was Peter Gouras,
who made microelectrode recordings in vivo from Macaca
mulatta and made a basic distinction between cells with transient
(“phasic”) responses and those with sustained (“tonic”) responses
(57). Influenced by the psychophysical work of Stiles (58), Gouras
presented small monochromatic flashes of varying wavelength on
monochromatic adapting fields and showed that sustained cells
typically drew inputs from one class of cone in the centre of their
receptive field and inhibitory inputs from other types of cone in
the surround. Given the specificity of the centre input and the
predominance of sustained cells in the central field, he identified
them with the midget cells of Polyak. The phasic cells were more
common in the periphery and appeared to draw inputs of the
same sign from long- and middle-wave cones, with little input
from short-wave cones.
In the last two decades, it has become possible to record
concurrently from several hundred ganglion cells in an eye-
cup preparation. A segment of peripheral retina, with pigment
epithelium intact, can be placed with ganglion cell layer
downwards on a planar array of, say, 512 extracellular micro-
electrodes. In the work of Field et al. for example, the macaque
retina was stimulated with a lattice of square pixels that
varied randomly and independently in chromaticity (59). The
responses of individual ganglion cells, identified later off-line,
were correlated with the random pattern of stimulation to
determine their preferred stimuli.
The introduction of adaptive-optics scanning-light
ophthalmoscopy (AOSLO) combined with calcium imaging
has been used to monitor the responses of individual ganglion
cells in the eye of a living primate [e.g., (60)]. Action potentials
cause rapid changes in intracellular free calcium and these can
be revealed with a fluorescent protein calcium sensor. McGregor
et al. used the sensor GCaMP6s for that purpose. While the
retina was stimulated with orange (590 nm) drifting gratings, a
488-nm laser was focussed on the ganglion cell layer to excite
the calcium sensor, and the fluorescence was detected in a band
at 517–520 nm. A limitation of currently available calcium
sensors, such as GCaMP6s, is that they have relatively large
time constants (0.6 s) and so cannot follow high frequencies
of modulation.
Combinations of Methods
A critical task has been to relate one method of classification
to a second. An early success was achieved by intracellular
recording with a micropipette electrode filled with a dye such
as Procion yellow (61): after a basic characterisation of the cell’s
response, the passage of hyperpolarizing current could be used to
inject the stain into the cell, for later histological examination.
Nelson et al. used such a method in eye-cup preparations
from cat to show the fundamental mammalian separation of
the inner plexiform layer into ON and OFF sublaminae (62).
Dacey and Lee used a refinement of this technique in which
primate ganglion cells of specific morphology were targeted in
a flat-mount preparation under visual inspection, recordings
were made with an intracellular micropipette, and the cell was
stained by intracellular injection of the fluorescent dye pyranine
during recording (63). It was this work that first identified the
small bistratified ganglion cell as carrying the excitatory signal of
short-wave primate cones.
In 2003, Dacey et al. introduced a powerful technique that
has been central to our modern understanding of the range of
ganglion cell types (64). The method allows the morphology
of the cell to be related not only to stratification level in the
inner plexiform layer and to downstream projection sites, but
also to the functional characteristics of the cell. Rhodamine
dextran was injected in vivo into a central site (e.g., the lateral
geniculate nucleus or the superior colliculus) and the dye
travelled retrogradely to the retina over the course of 4 to 7
days. In a subsequent in vitro preparation of retina, including the
retinal pigment epithelium (RPE) and choroid, the rhodamine
dextran was seen to be sequestered within the cytoplasm of
ganglion cell bodies, but if, under visual inspection, an individual
cell was briefly exposed to light, then the tracer was liberated and
spread throughout all the processes of the cell. The tracer did not
appear to impair neuronal function, and the responses of the cell
could be examined with an extracellular microelectrode, while
visual stimuli were delivered via themicroscope used for selecting
cells and placing the electrode (64).
Peng et al. have linked their single-cell RNA analyses to
morphology by combining fluorescent in situ hybridisation
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FIGURE 3 | Receptive fields and responses of ON-centre, OFF-centre, and ON/OFF retinal ganglion cells. ON-centre RGCs (upper panels) increase their rate of
discharge when the light illuminates in the centre. However, when the surround field is illuminated, the ON-centre RGCs are suppressed. OFF-center RGCs respond
when the light turns off (middle panels). ON/OFF cells are triggered briefly when the light turns on or off (lower panels) (by Ungsoo S. Kim).
(“FISH”) with sparse viral labelling (19). By this means, they were
able to confirm—for ON- and OFF-midgets and ON- and OFF-
parasols—the tentative identifications that had emerged from
their analyses of RNA patterns.
Types of Retinal Ganglion Cells
Although there is some degree of consensus on major retinal
ganglion cell types including midget RGCs, parasol RGCs
and small bistratified RGCs, there has been some debate
over classification of the remaining types. The functions of
the remaining RGCs have been inferred from animal studies
(Table 4).
Midget RGCs (P-Cell, mRGCs)
This major cell type accounts for 70% of RGCs. The
midget RGCs have a small-sized body with small fields of
dendrites (5–10µm in diameter in the central retina and up
to 225µm in the periphery), which correspond to smaller
receptive fields than those of other RGCs. These cells are
located mainly in the central retina and project to the
parvocellular pathway (66, 67). Midget RGCs have a one-
to-one connectivity with midget bipolar cells, which draw
their input from a single cone (68). There are two types of
midget RGCs: the outer stratified OFF-midget cells show smaller
dendritic fields and higher cell densities than the inner ON-
midget cells.
The parvocellular pathway is dominated by midget RGCs.
Functional assessments of these cells demonstrate that their
luminance contrast sensitivity is lower than that of parasol
RGCs and most show clear chromatic opponency (69). In
general, midget cells have red–green opponency, parasol RGCs
are achromatic, and bistratified ganglion cells connect with S-
cone ON and L-M cone OFF pathways. However, recent studies
suggest that some OFF-midget cells receive signals from short
wavelength (blue) sensitive cones (14, 70). Electron microscopy
reconstructions of retinal circuits suggest the possibility that a
small proportion of midget ganglion cells might have blue–OFF,
yellow–ON receptive fields. In addition to colour discrimination,
midget RGCs also subserve pattern, texture and stereoscopic
depth perception (71).
Parasol RGCs (M-Cell, pRGCs)
Parasol RGCs project to the magnocellular layer of the LGN. As
with midget cells, there are two types of parasol cells in primates:
ON-parasol cells respond with an increase in firing rate at the
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TABLE 4 | The classification of retinal ganglion cells in primates.
Stratification Dendritic field size (µm) Function
Midget Inner (above the axon terminals of DB6 bipolar cells)
Outer (CD15-labeled OFF midget bipolar cells)
10–100µm Colour (red-green)
Parasol Inner (above the DB6 cells)
Outer (at the level of the calbindin-labelled DB3a cells)
30–300µm Movement
Small bistratified Inner (above the level of DB6 axons)








Outer (calbindin-labelled DB3a cells)/Inner (DB6 cells) 190–300µm
Broad thorny In the middle of IPL (DB3a cells to CD15-labeled DB6 cells) 170–600µm Local edge detectors?
Recursive bistratified DB6 cells ON-OFF direction
Recursive monostratified
Large sparse 240–333µm
Giant sparse Bistratified (65) (Inner / Outer) 441–533µm
Nomenclature by Masri et al. (8).
onset of light in the centre of their receptive field whereas OFF-
parasol cells react to off stimuli (63). In synaptic connexions
between ON-centre parasol cells and other cells, ∼20% of the
input is from bipolar cells and the remainder of the signal is
introduced from amacrine cells (72).
Parasol RGCs have larger receptive fields and cell bodies, have
higher sensitivity to luminance contrast, and present little or no
chromatic antagonism, in contrast to midget RGCs (73). Parasol
RGCs play a role in motion perception, flicker perception and
depth processing based on motion parallax (71). They largely
comprise the magnocellular pathway.
Small Bistratified RGCs
This cell type accounts for ∼5–8% of RGCs (8). The small
bistratified RGCs (sbRGCs) project to the koniocellular layers
of the LGN. Small bistratified cells have branches in both
layers (inner ON- IPL and outer OFF-IPL): inner ON-
IPL branches receive excitatory input from S-ON bipolar
cells initiated by S-cones, while opposed (L+M)-OFF light
responses arrive through outer OFF-IPL branches (63). This
arrangement is thought to give good colour vision with low
spatial resolution.
Large Bistratified RGCs
The inputs of large bistratified RGCs have not been elucidated.
Large bistratified cells may receive not only S-cone ON-pathway
input, but also (L+M) cone OFF-opponency (inhibitory) signals.
However, the precise role of this cell type is not yet clear (74).
Smooth Monostratified RGCs
Smooth monostratified RGCs (smRGCs) have irregular receptive
fields with multiple distinct hotspots of light sensitivity. These
cells again can be divided into ON- and OFF-cells (75).
They might contribute to signalling spatial information via a
non-linear mechanism, whereby output is not linearly related to
input (76).
Recursive Monostratified/Bistratified RGCs
The recursive RGCs have moderately densely branched dendritic
trees in which many secondary branches tend to curve back
towards the soma or close loops of apposing and recursive
dendrites. In addition, many dendrites overlap those of
neighbouring cells (77). These features resemble those of the
directionally selective, motion-sensitive RGCs (dsRGCs) of the
rabbit, in which seven types of dsRGCs have been described,
namely, ON-types specific to three different directions and ON-
OFF types, specific to four different directions. To date, only one
population of a bistratified ON-OFF type has been described in
the macaque retina (78–80).
Thorny RGCs
There are three types of thorny RGCs in the primate retina that
account for ∼1% of ganglion cells (77). Broad thorny RGCs are
given various names such as thorny diffuse, T-group cells, S3
narrow thorny, and hedge cells (30, 49, 81). The dendrites of
broad thorny RGCs span a whole layer of the inner plexiform
layer. It is presumed that the cells may contribute to ON/OFF-
centre light responses that are strongly suppressed by stimulation
of the receptive field surround, such as local edge detector cells in
rabbits (82). Additionally, two narrowly stratified cells, including
outer and inner, are found in primates and their connectivity has
not been clarified yet.
Large Sparse RGCs
These cell types are monostratified cells that receive input
from amacrine and bipolar cells. The transcription factor Satb2
is expressed in large sparse RGCs in macaque and human
retina (83).
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Melanopsin-Containing Intrinsically Photosensitive
RGCs (ipRGCs)
The ipRGCs constitute 1% of the total RGC population in
humans (84). These cells have large, sparse dendritic fields. They
are intrinsically photosensitive because of the expression of the
melanopsin photopigment and capable of phototransduction
independently of rods and cones (84). In mouse retinas,
six subtypes (M1, M2, M3, M4, M5, and M6) of ipRGCs
have been identified with distinctive anatomical and functional
properties (Figure 4) (85). M1 and M2 ipRGCs account for
the majority (74–90%) of ipRGCs. The main function of
ipRGCs, in particular of the Brn3b-M1subtype, is to contribute
to circadian photoentrainment through the projections to the
suprachiasmatic nucleus (SCN) of the hypothalamus (86), but
they are also relevant for other non-image forming functions
of the eye, including the regulation of the pupillary light reflex
through the projections to the OPN. M1 and M2 ipRGCs project
to both the SCN and the olivary pretectal nucleus (OPN);
however,M1 ipRGCs innervate the outer shell region of the OPN,
where projection neurons that innervate the pre-autonomic
Edinger-Westphal nucleus reside, whilst M2 ipRGCs innervate
the OPN central core (87). The input dendrites of M2 and M4
ipRGCs are in the inner retina (ON-pathway), whereas those
of M1 ipRGCs are located near the inner nuclear layer (OFF-
pathway). The dendrites of M4 and M5 ipRGCs are located in
the inner lamina of the inner plexiform layer. M4 ipRGCs have
a larger cell body compared with M5 ipRGCs that have small,
highly branched dendrites arrayed uniformly around the soma.
In humans, three ipRGC subtypes (M1, M2, and M4) have
been defined (88). M1 ipRGCs have outer stratifying dendrites
with a few smooth spines in the outer IPL, whereas M2 ipRGCs
stratify in the inner part of the inner plexiform layer (IPL)
close to the ganglion cell layer. M1 ipRGCs have been divided
into two subtypes, gigantic M1 RGCs (GM1 cells) with round
or oval large soma and displaced M1 RGCs (DM1 cells). Both
ipRGC types receive inputs from DB6 bipolar cells and project
to the dorsal LGN (89). M2 ipRGCs have larger soma and more
branched dendrites thanM1 ipRGCs. M1 ipRGCs are reported to
receive an inhibitory input from short-wave cones via an S-cone
amacrine cell (90), whereas M2 ipRGCs receive input from S-On
bipolar cells and contribute to the blue cone pathway (91). M1
ipRGCs project to the SCN to synchronise the circadian clock
and M2 ipRGCs project to the OPN in the thalamus to control
pupillary response.
The ipRGCs are relatively preserved in the mitochondrial
optic neuropathies, such as Leber hereditary optic neuropathy
(LHON) and autosomal dominant optic atrophy (ADOA).
However, ipRGCs are affected in other optic neuropathies, such
as glaucoma, and late-onset neurodegenerative disorders, such as
Alzheimer disease and Parkinson disease (92–95).
Miscellaneous RGCs
There are a small number of unclassified RGCs in primates
that do not fit with any of the previously described RGCs (8).
Further work is needed to elucidate the characteristics of this
miscellaneous group of RGCs.
Clinical Aspects of RGC—Methods of
Assessment and Clinical Entities
Clinical Structural and Functional Assessment of
RGCs
Although RGCs have been extensively studied in primates, the
clinical assessment of RGCs has proven more challenging as they
cannot be evaluated directly.
Structural Quantification of RGCs
Optical Coherence Tomography
Optical coherence tomography (OCT) is a non-invasive imaging
technique that uses low-coherence light waves to capture a
cross-section of various tissues. Major advances have led to the
development of spectral domain OCT, which can produce a
segmentation of ten layers of retina, including the retinal nerve
fibre layer (RNFL) and ganglion cell layer. OCT has become a
standard tool to investigate changes with RGCs as it is non-
invasive, rapid, highly reproducible (96–98).
The RNFL can be measured in both the peripapillary and
the macular areas. Several studies suggest that changes can be
detected earlier by assessing the thickness of the RNFL in the
macula compared with the peripapillary RNFL, owing to the
latter’s thickness (99, 100). There is a good correlation between
RNFL thickness and both visual acuity and visual field changes,
offering an objective structural parameter for assessing glaucoma
and other optic neuropathies (101–103). However, to avoid
misinterpretation of OCT, several factors need to be considered:
segmentation errors can occur particularly in the presence of a
tilted optic disc (104); and RNFL thickness is also affected by age
as well as by refractive error and axial length. In addition, there
is lag time before any changes in the thickness of the RNFL can
be detected after disease onset (105), and the thickness can be
overestimated in the presence of optic disc or RNFL swelling.
In addition, RNFL thickness exhibits a floor effect that must
be considered in advanced optic neuropathies. RNFL thinning
reaches a trough at a certain level owing to residual tissues such as
vessels and glial cells (106, 107). Furthermore, RNFL loss usually
signifies irreversible damage and functional tests (as described
below) might be needed to identify ganglion cell dysfunction at a
potentially reversible stage. It is well-established that visual acuity
and visual fields can recover despite extensive RGC layer thinning
(108, 109).
Microcysts in the inner nuclear layer have been reported
on macular OCT imaging in some patients with advanced loss
of macular RGCs. These are thought to arise from retrograde
transsynaptic degeneration and/or vitreous traction in the
presence of RGC and RNFL loss (110, 111). They do not seem
to be specific to a particular aetiology, having been reported
in patients with inherited optic neuropathies, demyelinating
optic neuritis, compressive and nutritional optic neuropathies,
endemic optic neuropathy and advanced glaucoma (112–114).
It is not clear why these microcysts develop in only a subgroup
of patients. They are seen more often in younger patients who
may have a more adherent vitreous surface and ILM tension has
been implicated as part of the pathophysiology (110). However,
microcysts have also been reported as a long-term consequence
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FIGURE 4 | Melanopsin-containing intrinsically photosensitive RGCs in primates. Inner stratifying ipRGCs (M2 ipRGCs) have larger soma and more branched
dendrites than outer stratifying ipRGCs. In addition, the dendrites of M1 ipRGCs are mainly located in the outer IPL layer, whereas M2 ipRGCs are in the outer IPL
layer close to the ganglion cell layer. M1 ipRGCs project to the suprachiasmatic nucleus (SCN) to synchronize the circadian clock and M2 ipRGCs project to the olivary
pretectal nucleus (OPN) in the thalamus to control pupillary response. A, amacrine cell; Off-B, Off-bipolar cell; On-B, On-bipolar cell (by Ungsoo S. Kim).
associated with RGC loss in patients with silicon oil-related visual
loss (115). These patients have undergone prior removal of the
vitreous suggesting that simple vitreous traction may not be
sufficient to explain the development of these microcysts.
Detection of Apoptosing Retinal Cells
The detection of apoptosing retinal cells (DARC) is a new
technique that enables visualisation of real-time RGC apoptosis
using fluorescently-labelled annexin A5. This 36 kDa protein is
expressed in humans and it is a well-established indicator of
apoptosis (116)). DARC has the advantage of early detection of
RGC loss before visual deterioration has occurred, and it being
considered for the evaluation of optic neuropathies, including
glaucoma disease progression (117).
Functional Evaluation of RGCs
A number of psychophysical measurements can be used to
investigate changes in RGC function.
Visual Acuity Tests
Visual acuity has been defined as the “spatial resolving capacity”
of the visual system and it is the most common primary outcome
measure in clinical trials. Although Snellen charts are widely
used, the LogMAR scale based on the Early Treatment Diabetic
Retinopathy Study (ETDRS) chart is the gold standard for clinical
trials, overcoming many of the limitations of Snellen charts.
However, as visual acuity tests central foveal function, patients
can have widespread ganglion cell loss with preserved central
visual acuity.
Spatial and Temporal Contrast Sensitivity Tests
Achromatic stimuli of low and high spatial frequencies can
be used to differentiate responses from the magnocellular and
parvocellular systems. The magnocellular pathway has lower
spatial resolution and responds to higher temporal frequencies
than the parvocellular pathway (118). However, this difference is
relatively small and the two pathways have a degree of overlap.
Colour Vision Tests
Colour vision impairment is a frequent feature of ganglion
cell pathology, but outer retinal dysfunction can also affect
colour vision, such as anomalies of the cone photoreceptors.
Congenital stationary red-green colour deficiencies commonly
affect men, owing to loss or alteration of the long or medium
wavelength opsin genes on the X-chromosome (119). Rarely,
abnormalities in the same genetic region can give rise to S-
cone monochromacy. Congenital tritan anomalies, arising from
abnormalities in S-cones are also rare. Progressive or later onset
cone or macular dystrophies, or congenital achromatopsia, will
also affect colour vision, but in these conditions visual acuity is
also usually impaired (120). In acquired ganglion cell pathology,
however, visual acuity can be preserved with colour vision being
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preferentially affected. Many optic neuropathies affect red-green
discrimination, although glaucoma commonly affects the blue-
yellow axis (120).
Colour vision tests are widely used to screen patients with
congenital colour vision defects and to investigate acquired
pathology. There are three broad types of colour vision
tests in practice (121). Pseudoisochromatic tests, such as the
Ishihara, the Hardy-Rand-Rittler (HRR), and the Standard
Pseudoisochromatic Plates (SPP), the Colour Vision Testing
Made Easy (CVTME), and the Cambridge Colour Test are widely
used. In arrangement tests, such as the Farnsworth-Munsell (FM)
Dichotomous D-15 tests and 100-hue test, the patient is required
to arrange a set of colours in order. The FM 100-hue test is highly
sensitive, but time-consuming. Lastly, anomaloscopes are based
on colour-matching where the observer adjusts a mixture of red
and green lights to match a monochromatic orange light.
As congenital anomalies of colour perceptionmore commonly
affect red-green discrimination, many standard tests such as the
Ishihara plates and the Nagel anomaloscope do not probe for
tritan disorders, which are common in acquired pathologies.
Tritan defects can be identified readily by other tests, including
the D-15 and FM 100-hue, the Cambridge Colour Test, and
the HRR plates. In addition, more specialised psychophysical
methods, including measurement of the three primary colour
vision mechanisms, colour adaptometry, and colour perimetry
can be applied (122). Among them, SWAP, a specialised type
of perimetry, can also be considered a colour vision test, as the
targets are short-wave and the field is of long wavelength and
high intensity (in order to adapt the long- and middle-wave
cones) (123).
Visual Field Tests
In addition to conventional visual field testing, short wavelength
automated perimetry (SWAP) probes the small bistratified
ganglion cells and the konioceullar pathway, and high-pass
resolution (ring) perimetry tests the parvocellular pathway,
whereas flicker perimetry, motion perimetry, and frequency
doubling technology (FDT) target the magnocellular pathway
(124). Among these tests, SWAP and FDT are available as
commercial products.
(1) Frequency Doubling Technology (FDT)
FDT has the advantage of greater sensitivity, potentially
detecting RGC damage earlier than standard automated
perimetry (SAP) (125). Modern FDT uses targets of low spatial
frequency that flicker at a high temporal frequency and that
predominantly stimulate the magnocellular pathway, which
corresponds to motion detection and flicker detection (126).
FDT has been put forward for the early detection of glaucoma
on the basis that the magnocellular pathway is more vulnerable
in glaucoma (127, 128). However, there is evidence that both
the parvocellular and magnocellular pathways are affected early
in glaucoma with no significant differences between these two
pathways in terms of their vulnerability (129). Furthermore, a
recent study indicated that FDT is neither sensitive nor specific
as a screening tool for glaucoma (130). Further studies are,
therefore, needed to evaluate the role of FDT in the early
detection of glaucoma.
(2) Short Wavelength Automated Perimetry (SWAP)
Unlike standard visual field testing, which uses a white
stimulus on a white background, SWAP employs a blue stimulus
on a yellow background. Several studies suggested that SWAP is
more sensitive for the early detection of glaucomatous changes
compared with standard visual field testing (131–133). There
is, however, no definitive evidence that the small bistratified
ganglion cells (short-wave response) are more vulnerable in
glaucoma. SWAP was reported to be 10–20 times more sensitive
than standard perimetry in patients with ADOA (134). As a
result, SWAP was able to differentiate between normal tension
glaucoma with or without OPA1 polymorphism (135). However,
SWAP has some limitations as it is time-consuming, it needs
a higher level of cooperation, and it has lower reproducibility
compared with standard perimetry (136).
Chromatic Pupillometry
The primate pupil responds to signals from ipRGCs, which
additionally receive input derived from cone responses.
Chromatic pupillometry uses selective wavelengths to quantify
pupil size before, during, and after a light stimulus has been
applied. Comparison of pupillary responses to short-wavelength
and long-wavelength light can selectively probe the function of
outer retinal photoreceptors or the intrinsic response of ipRGCs.
The ipRGCs are blue light sensitive and maximally sensitive to
wavelengths that lie between the peak sensitivities of the rods
and S-cones. Several studies using chromatic pupillometry in
experimental animal models have shown that the light sensitive
ipRGCs were spared in retinitis pigmentosa characterised by
marked photoreceptor loss (137). Generally, the ipRGCs are
relatively preserved in mitochondrial optic neuropathies, such
as LHON and ADOA (138, 139), but affected in other optic
neuropathies such as glaucoma, non-arteritic anterior ischemic
optic neuropathy and demyelinating optic neuritis (140).
Bichromatic pupillometry has been used to differentiate between
mitochondrial and non-mitochondrial optic neuropathies
(94, 140).
Electrophysiological Tests
Electrophysiology allows direct objective assessment of electrical
responses in vivo. The visual evoked potential (VEP), recorded
over the visual cortex, has long been used as a means of assessing
the function of the visual pathway, as well as demonstrating
developmental abnormalities, such as the misrouting of ganglion
cell axons in albinism (141). In addition, the electroretinogram
(ERG), which represents the summed electrical response of the
retina to light stimuli, can be recorded non-invasively. The
pattern ERG (PERG), arising from stimulation of the macula, is
largely derived from responses in the macular RGCs. In contrast,
the full-field ERG, which is generated from the stimulation of
the whole retina, is usually used to evaluate responses from
photoreceptors and bipolar cells. However, a late component, the
photopic negative response (PhNR) has been shown to arise in
ganglion cells.
(1) Pattern Electroretinogram
The PERG is recorded in response to a patterned stimulus
(typically a checkerboard pattern reversing 4 times per second),
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which stimulates the central 15 degrees of the retina (142).
The PERG comprises a cornea-positive wave at 50ms (termed
P50) and a negative wave at 95ms (termed N95). The test is
performed in photopic conditions with undilated pupils and
it requires optimal refraction. The response is driven by the
macular cone photoreceptors, but it appears to arise largely
from the macular RGCs, whose signals appear to give rise to
the N95 component and the majority of the P50 component
(143, 144). Various optic neuropathies that affect the ganglion
cells within the retina (either as the primary site of impairment
or from retrograde degeneration from an optic nerve lesion), for
example demyelinating optic neuritis, ischemic optic neuropathy,
compressive optic neuropathy, toxic optic neuropathy, and
inherited optic neuropathies can result in a reduction of the N95
and P50 amplitudes, with N95 being reduced more than P50, and
a shortening of the P50 peak time (145–147). Whilst the PERG
is sensitive to macular RGC dysfunction, precise correlation
with RGC subtype is not known, and the test will not detect
extramacular RGC impairment.
(2) Photopic Negative Response
The PhNR is a negative wave of long latency that follows the
b-wave of the photopic cone-driven ERG and it arises in RGCs
(148). Whilst it can be detected in standard white-on-white flash
responses, specific chromatic protocols can be used to optimise
the PhNR signal (149). As with the PERG, the amplitude of
the PhNR decreases in optic nerve disorders (150, 151). Unlike
in PERG recordings, optimal refraction is not needed, but the
pupils need to be dilated. In addition, a hand-held mini-Ganzfeld
stimulator is available to test PhNR (152). The flashes stimulate
the retina as a whole so the PhNR can be indicative of global
RGC function.
Focal PhNR recordings can be performed to assess RGCs over
a particular region (typically the macula) (153). The PhNR can
be used to examine the parvocellular pathway whereas the steady-
state PERG is focused on the magnocellular pathway in glaucoma
(154). Although the PERG and PhNR can detect glaucoma, there




Inherited and acquired optic neuropathies are important causes
of registrable blindness. Treatment options remain limited, and
when available, they mostly slow down or prevent further loss
of RGCs. Visual loss is usually irreversible although in some
cases, spontaneous visual recovery can occur owing to the
functional recovery of RGCs that have not undergone apoptosis.
To better inform future treatment strategies, it is essential to
gain a better understanding of the pattern of RGC loss and
whether different aetiological triggers result in global or more
selective loss of RGCs, and how these relate to the visual deficits
and eventual outcome. It remains a challenging task as patients
are not always examined in the acute stage of the disease and
serial measurements are needed to document progression over
time. Nevertheless, we are gaining a better understanding of the
structure-function relationship in different optic neuropathies
aided by the availability of high-resolution retinal imaging with
OCT and more sophisticated visual electrophysiological and
psychophysical tools (Figure 5).
Inherited Optic Neuropathies
The minimum prevalence of inherited optic neuropathies has
been estimated at 1 in 10,000 (156). This group of disorders
is genetically heterogeneous with disease-causing mutations
occurring in both mitochondrial and nuclear DNA (157).
Remarkably, all genes identified to date encode proteins
that are either directly or indirectly involved in regulating
mitochondrial function. The generation of ATP by the
mitochondrial respiratory chain is central to cell survival
and mitochondria also regulate other key pathways, including
the level of reactive oxygen species and the tight control of
apoptosis. An intriguing aspect of inherited optic neuropathies
is the preferential vulnerability of RGCs compared with other
neuronal populations despite the ubiquitous expression of the
genes involved. There have been limited post mortem studies on
the pattern of RGC loss in inherited optic neuropathies owing to
the lack of access to diseased human tissues. Nevertheless, useful
insight has been obtained with the application of high-resolution
OCT imaging and psychophysical evaluation of patients at
different stages of the disease process. The two best studied
inherited optic neuropathies are LHON and ADOA.
(1) Leber Hereditary Optic Neuropathy
LHON is a primary mitochondrial DNA (mtDNA) disorder
and ∼ 90% of cases are due to one of three mtDNA point
mutations, namely, m.3460G>A (MT-ND1), m.11778G>A (MT-
ND4), and m.14484T>C (MT-ND6) (158, 159). The peak age
of onset is from 15 to 35 years old and the majority of patients
are men (80–90%) (160). Although bilateral simultaneous onset
can occur in some patients, sequential involvement of the
second eye within a few months is more typical. LHON
is characterised by severe visual loss with dyschromatopsia
and a dense central or cecocentral scotoma on visual field
testing. OCT initially shows swelling of the RNFL, follows by
marked thinning of RNFL, especially in the temporal quadrant
corresponding to the papillomacular bundle (161). Childhood-
onset LHON and the m.14484T>C mutation are associated
with a more favourable visual outcome (38, 162). Most patients
with LHON are registered legally blind with <20% of patients
carrying the m.11778G>A mutation experiencing some visual
recovery (159, 163).
In LHON, RGCs with the smallest calibre axons, which
have smaller mitochondrial reserve per energy requirement,
are preferentially affected and these are predominantly located
within the papillomacular bundle (164, 165). The peripapillary
RNFL is swollen in the acute stage of LHON, as demonstrated
by OCT, with subsequent thinning occurring as the disease
progresses into the chronic stage. Measurement of ganglion cell
and inner plexiform layer (GC-IPL) thickness in the macular
area indicate that pathological thinning is already evident in the
pre-symptomatic stage about 6 weeks before the onset of visual
loss in the fellow eye (166). These findings suggest that midget
RGCs, which are a major component of the papillomacular
bundle, could be more vulnerable to the underlying mtDNA
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FIGURE 5 | Pattern of RGC involvement in optic neuropathies. The types of RGCs affected in inherited optic neuropathies and acquired optic neuropathies are
indicated by black and red lines, respectively. The dotted green line indicates the preservation of ipRGCs in inherited optic neuropathies. ADOA, autosomal dominant
optic atrophy; FDT, frequency doubling technology; ipRGCs, intrinsically photosensitive retinal ganglion cells; LHON, Leber hereditary optic neuropathy; mRGCs,
midget retinal ganglion cells; pRGCs, parasol retinal ganglion cells; sbRGCs, small bistratified retinal ganglion cells; smRGCs, smooth monostratified RGCs; SWAP,
short wavelength automated perimetry (by Ungsoo S. Kim).
mutation. Selective attenuation of four of the six layers in
the LGN that are connected to the parvocellular pathway
have been reported, but this feature is controversial as the
magnocellular pathway is known to be also affected in LHON
(167, 168). Further investigations are needed to determine the
primary defect.
The ipRGC subtype is relatively preserved in LHON,
explaining why the pupillary light reflex is maintained even
in severely affected patients (138). The mechanisms that
account for this enhanced resilience of ipRGCs remain unclear,
although several hypotheses have been proposed (140). From
an anatomical perspective, ipRGCs are predominantly located in
the parafoveal area and at the far end of the nasal hemiretina,
rather than feeding into the papillomacular bundle (92). In a
post mortem study of a patient carrying them.3460G>AmtDNA
mutation, the pupillary fibres in the pretectum were found to be
preserved (169). It is possible that ipRGCs are protected because
of their higher concentration of mitochondrial cytochrome
c oxidase and a greater abundance of mitochondria (140).
Several protective factors such as PI3K and pituitary adenylate
cyclase-activating polypeptide (PACAP) may further reinforce
the survival of ipRGCs under certain conditions (170, 171).
(2) Autosomal Dominant Optic Atrophy
ADOA is the most common inherited optic neuropathy with
an estimated prevalence of 1 in 25,000 in the general population
(172). Mutations in the nuclear gene OPA1 (3q28-q29) account
for ∼70% of all cases of ADOA (173). The classical clinical
features of ADOA are progressive bilateral visual loss starting
in early childhood, dyschromatopsia, a central or cecocentral
scotoma, and optic disc pallor that is more prominent temporally
due to the preferential involvement of the papillomacular bundle
(174). There is a marked variability in disease severity with
visual acuity ranging from 6/6 to light perception, and variable
rates of disease progression even within the same family (175).
OCT typically shows RNFL thinning, which is more marked
temporally, with gradual loss of RGCs occurring over time (176).
The disease process is thought to start in utero with OPA1
carriers having a reduced number of RGCs at birth compared
with normal healthy individuals (138).
In ADOA, midget RGCs, parasol RGCs and small bistratified
RGCs are all affected, impairing sensitivity to high spatial
frequencies, long- and middle-wave colour discrimination,
sensitivity to high temporal frequencies, and short-wave
sensitivity. The S-cone–related losses showed a significant
deterioration with increasing patient age and could therefore
prove useful biomarkers of disease progression in ADOA (177).
The S-cone chromatic response and koniocellular pathway
are impaired in the early stage of the disease, which suggest
a vulnerability of small bistratified RGCs (173). Although
tritanopia has been reported as the characteristic colour vision
defect in ADOA, only 7.5% of patients with ADOA had
exclusively tritanopia in one study, with the most common
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colour defect in 81.2% of patients being of the mixed
type (134).
As in LHON, the pupillary response in ADOA is relatively
preserved, indicating that ipRGCs in mitochondrial optic
neuropathies appear to be more resistant to the underlying
mitochondrial dysfunction compared with other RGC subtypes.
Studies using chromatic pupillometry also reported preservation
of ipRGCs in ADOA patients with severe visual loss and optic
atrophy (178, 179).
Acquired Optic Neuropathies
There is a long list of aetiological factors that can result in RGC
injury and optic nerve degeneration. Compared with inherited
optic neuropathies, fewer studies have focused specifically on
RGC pathophysiology in acquired optic neuropathies. More
work is, therefore, needed to elucidate subtype selectivity, if
any, of RGC loss in ischemic, compressive, inflammatory,
autoimmune and paraneoplastic optic neuropathies. However,
we do know that most toxic optic neuropathies have an
underlying mitochondrial aetiology (180). There is a growing
body of evidence that mitochondrial dysfunction plays a
prominent pathophysiological role in glaucoma, demyelinating
optic neuritis and toxic optic neuropathies (181, 182). This
aetiological link is relevant and comparing the pattern of RGC
loss between these acquired optic neuropathies and classical
monogenic optic neuropathies could reveal common pathways
amenable to therapeutic intervention.
(1) Glaucoma
Glaucoma is a leading cause of irreversible blindness affecting
3–5% of the population over the age of 70 years (183). Extrafoveal
RGCs usually deteriorate in the early stages resulting in arcuate
scotomas in the visual field. Traditional anatomical studies
reported greater loss of axons of large diameter, corresponding
to the magnocellular pathway (parasol cells) (184), and the
magnocellular LGN layers were more affected compared with the
parvocellular LGN layers (185). However, there are rarer types of
retinal ganglion cells with large axons and further investigations
are needed to evaluate the changes of these cells in glaucoma.
The relative vulnerability of large axons in glaucoma may
simply reflect the anatomical location of the affected ganglion
cells. Glaucoma patients have poor response to high temporal
frequency light stimuli that correspond to the magnocellular
pathway. In a primate study using immunohistochemistry,
a decrease in large RGCs was observed after elevating IOP
(186). This specific vulnerability was ascribed to calcium-
permeable receptors, the relative proximity of RGCs and their
dendrites to blood supply in the IPL layer, and the differing
metabolic requirements of these particular large cell types (187).
However, other studies suggested no predilection for a specific
pathway (188, 189). Compared with inherited optic neuropathies,
the ipRGCs are vulnerable in both patients with confirmed
glaucoma and glaucoma suspects (190, 191). In contrast, ocular
hypertension does not seem to result in significant loss of
ipRGCs (192).
(2) Demyelinating Optic Neuritis
Inflammatory demyelination resulting in optic neuritis is a
major manifestation of multiple sclerosis. Inflammation of the
retinal vascular endothelium can precede demyelination and
perivascular cuffing and oedema of the optic nerve sheath leads
to breakdown of myelin (193). Idiopathic demyelinating optic
neuritis leads to visual loss with minimal axonal loss.
Optic neuritis is associated with alteration of both the
parvocellular and magnocellular pathways (194). Viret et al.
suggested that the more heavily myelinated magnocellular axons
are more vulnerable in patients with optic neuritis because low
spatial frequencies, which are transmitted by the magnocellular
pathway, are affected predominantly 1 month after the acute
phase of the optic neuritis episode (195). Despite the recovery of
visual acuity, the magnocellular pathway did not fully normalise
(196). In contrast, a significant loss at high spatial frequencies has
been reported in the affected eye and the parvocellular pathway
was more impaired in patients with resolved optic neuritis
who had 20/20 visual acuity after recovery (197). Fallowfield
and Krauskopf suggested that chromatic discrimination is
more severely impaired than luminance discrimination in the
demyelinating diseases (198). This discrepancy might be due
to differences in the timing and severity of optic neuritis.
Consequently, it is still unclear which pathway is more vulnerable
in the context of demyelinating optic neuritis (196). Both red-
green and tritan defects have been reported in optic neuritis
(199). Characteristics of colour deficiency may change over time
as assessed with the FM 100-hue test, with blue-yellow defects
being more common in the acute stage and red-green changes
being predominant in the chronic stage (200). It is possible,
of course, that the variability of symptoms in optic neuritis
reflects immunologically distinct conditions that differentially
affect different types of RGCs.
(3) Toxic Optic Neuropathy
Various substances such as ethambutol, isoniazid, linezolid,
chloramphenicol and methanol can cause optic nerve
dysfunction, probably through acquired mitochondrial
dysfunction (180). As in inherited optic neuropathies, the
papillomacular bundle is selectively vulnerable and this typical
feature can be confirmed by optical coherence tomography,
which shows a profound decrease in temporal RNFL thickness.
The parvocellular pathway within the papillomacular bundle
is affected extensively likely secondary to a number of factors,
including smaller and more thinly myelinated nerve fibres
and a faster firing response with higher average rates of action
potentials (201). However, there is a lack of evidence on whether
this is simply because the parvocellular neurons predominate in
the papillomacular bundle, or whether the midget cells are the
primary target of the triggering toxic substances.
Clinical Relevance and Future Work
The physiological features of the major RGC subtypes (mRGCs,
pRGCs, and sbRGCs) are well-known, but the role and
characteristics of other RGCs require further study. An in-
depth characterisation of the chronological structural and
functional changes occurring within the RGC layer in optic nerve
disorders, including inherited and acquired optic neuropathies,
are important to inform the future design of clinical trials.
Understanding which RGC subtypes are selectively affected will
help optimise outcome measures in natural history studies and
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trials of experimental therapies. As mentioned earlier, the FDT
test is used for the early detection of glaucoma because the
magnocellular pathway is more vulnerable (127). Given that
a common variant in the SIX6 gene (rs33912345) is strongly
associated with primary open-angle glaucoma (POAG) and the
fact that this gene is highly expressed in midget RGCs, tests
that evaluate this particular cell type could prove to be a useful
sensitive biomarker of disease progression (19, 202).
The remarkable advances in gene delivery and editing
technology have led to an increasing number of clinical trials
for optic neuropathies, in particular gene replacement therapy
for monogenic inherited optic neuropathies (203). Gene therapy
using adeno-associated viral vectors is currently favoured and
there is now cumulative evidence of its long-term safety and
efficacy in delivering gene constructs to retinal cells (204, 205).
Promising results have been obtained with allotopic expression
of the MT-DN4 gene in patients with LHON treated within
1 year of disease onset (206, 207). To enhance success of
gene therapy, optimised tissue-specific promoters, which control
expression of the therapeutic gene, are needed, and these could
potentially. be optimised for the relevant RGC subtype (208).
Genomic editing, such as the CRISPR-Cas system, and stem
cell therapy is an exciting development that has the potential to
revolutionise the treatment of ophthalmological disorders given
the eye’s relative ease of anatomical access and its relative immune
privilege (209, 210). The intriguing preservation of ipRGCs
in mitochondrial optic neuropathies needs to be investigated
further as the factors that confer this resilience would be obvious
therapeutic targets (211).
There is increasing interest in employing RGCs to restore
visual function in the retinal dystrophies marked by widespread
loss of rods and cones (212). Optogenetic therapies are
being developed to confer light sensitivity to inner retinal
neurons, which are spared in these forms of outer retinal
degeneration. Another approach is the use of electronic implants
to stimulate these inner retinal neurons so that visual signals
can be transmitted to the brain. A better understanding
of inner retinal connectivity, specifically that of RGCs, is
essential to optimise these innovative sight restoring strategies.
Elucidating the selective vulnerability of RGCs compared
with other retinal and neuronal cell types in inherited optic
neuropathies is key to developing targeted treatments for
this group of disorders. The availability of high-throughput
transcriptomic techniques that can be conducted at the single
cell level is an exciting development, providing us with
powerful tools to identify pathways that can be modulated for
generalizable, mutation-independent neuroprotective strategies
(213). Although appealing, regenerative medicine will require
not only the replacement of the missing RGCs, but also the
establishment of the sophisticated circuitry that allows the
integration of signals from various pathways to achieve a
reasonable degree of visual perception (214).
CONCLUSION
Ganglion cells constitute the output pathway of the retina,
transmitting highly processed and integrated signals to the visual
processing areas in the brain. Up to 18 types of RGCs have
been reported, constituting a sophisticated repertoire of cell types
each with specific attributes contributing to visual perception.
Future studies will further dissect the selectivity and timing of
impairment of RGC subtypes in various optic neuropathies and
how these could be modulated in the context of experimental
therapies. The refinement of tests to assess RGC structure and
function is relevant not only for clinical practise, but also for
deep phenotyping as part of natural history studies and to
define relevant outcome measures for clinical trials. We are now
entering an exciting translational phase for optic neuropathies
with the confluence of genetic breakthroughs and targeted
therapies giving hope that we will soon be able to slow or prevent
the irreversible loss of RGCs in these blinding diseases.
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